Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing prevalence of Chronic Respiratory Diseases
4.2.2 Research and Development in Drug Discovery for Respiratory Diseases in Paediatric
4.3 Market Restraints
4.3.1 Stringent Regulations for Drug Approval
4.3.2 Side Effects from Therapeutic drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Anti-Inflammatory Drugs
5.1.2 Bronchodilators
5.1.3 Combination Drugs
5.1.4 Corticosteroid
5.1.5 Monoclonal Antibodies
5.1.6 Others
5.2 By Disease
5.2.1 Asthma
5.2.2 Cystic Fibrosis
5.2.3 Bronchiolitis
5.2.4 Pneumonia
5.2.5 Idiopathic Pulmonary Fibrosis
5.2.6 Tuberculosis
5.2.7 Others
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Bayer AG
6.1.3 GlaxoSmithKline plc
6.1.4 Merck & Co
6.1.5 Boehringer Ingelheim GmbH
6.1.6 Regeneron Pharmaceuticals
6.1.7 AstraZeneca plc
6.1.8 F. Hoffmann-La Roche AG
6.1.9 Genetech Inc


7 MARKET OPPORTUNITIES AND FUTURE TRENDS